ClinicalTrials.gg
Not yet recruitingNCT06816745Updated Feb 10, 2025

Comparison of Physiological Effects of Two Types of High-Flow Oxygen Therapy in Tracheostomized Patients

An interventional study of Modified high flow tracheal oxygen and Standard high flow tracheal oxygen in Critical Care, Oxygen Therapy and Tracheostomy, sponsored by Jian-Xin Zhou. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-10.

Sponsored by Jian-Xin Zhou · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

High-flow nasal oxygen therapy offers benefits like precise oxygen delivery, flow-related positive end-expiratory pressure generation and improved lung function. High-flow oxygen therapy can be applied via tracheostomy as high-flow tracheal oxygen. While high-flow tracheal oxygen has been used to facilitate weaning, it has diminished physiological effects due to bypassing upper airways. To enhance its effectiveness, researchers developed a modified high-flow tracheal oxygen tube with a smaller expiratory end diameter to increase airway resistance and pressure. This is a prospective randomized crossover study that aims to compare the physiological effects of standard and modified high-flow oxygen therapy in tracheostomized patients.

Read the detailed description

High-flow nasal oxygen therapy has been shown to provide several physiological benefits, including precise control of the fraction of inspired oxygen, generation of flow-related positive end-expiratory pressure, increased end-expiratory lung volume, improved oxygenation, and enhanced carbon dioxide elimination. It has been widely utilized in managing acute hypoxemic respiratory failure and preventing hypoxemia after extubation.

High-flow oxygen therapy can be applied via tracheostomy as high-flow tracheal oxygen. Previous studies have reported successful cases of using high-flow tracheal oxygen to facilitate weaning from prolonged mechanical ventilation in patients with restrictive and obstructive pulmonary disorders. However, compared to high-flow nasal oxygen, high-flow tracheal oxygen exhibits significantly diminished physiological effects due to the bypassing of the narrow nasopharynx, glottis, and upper airway, as well as a more open circuit.

To address this limitation, the investigators have developed a modified high-flow tracheal oxygen tube with a reduced expiratory end tube diameter. This modification aims to create higher expiratory resistance and airway pressure, thus simulating the physiological effects of high-flow nasal cannula. This is a prospective randomized crossover physiological trial designed to compare the effects of standard and modified high-flow oxygen therapy in tracheostomized patients. Key physiological parameters will be assessed, including airway pressure, end-expiratory lung volume, vital signs, oxygenation, and respiratory workload.

02

Conditions studied

  • Critical Care
  • Oxygen Therapy
  • Tracheostomy

Keywords

  • high-flow tracheal oxygen
  • tracheostomy
03

In context

Lead sponsor

Jian-Xin Zhou is the lead sponsor of 11 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Tracheostomy with stable spontaneous breathing.

Exclusion criteria

Exclusion Criteria:

  1. Age younger than 18 years old
  2. Pregnancy
  3. Hemodynamic instability (mean arterial pressure \<60 mmHg, heart rate >140 or \<60 bpm)
  4. Respiratory and oxygenation instability (respiratory rate > 35bpm or oxygen saturation measured by pulse oximetry \<90%)
  5. Neuromuscular diseases or phrenic nerve injury
  6. Recent trauma or surgery to the trachea, esophagus, neck, chest, or stomach
  7. Pneumothorax or placement of a chest drainage
  8. to electrical impedance tomography (EIT) (implantable defibrillator)
  9. Anticipating withdrawal of life support
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Modified high flow tracheal oxygen

    Modified high-flow tracheal oxygen with flow rates of 40L/ min and 60L/min will be performed in tracheostomized patients.

    Procedure: Modified high flow tracheal oxygen

  • Experimental
    Standard high flow tracheal oxygen

    Standard high-flow tracheal oxygen with flow rates of 40 L/min and 60 L/min will be performed in tracheostomized patients.

    Procedure: Standard high flow tracheal oxygen

Interventions

  • ProcedureModified high flow tracheal oxygen

    Modified high-flow tracheal oxygen with flow rates of 40L/min and 60L/min will be performed.

  • ProcedureStandard high flow tracheal oxygen

    Standard high-flow tracheal oxygen with flow rates of 40 L/min and 60 L/min will be performed.

06

What researchers measure

Primary outcomes

  1. Mean expiratory airway pressure

    Mean expiratory airway pressure will be measured during standard and modified high-flow tracheal oxygen.

    Time frame: From enrollment to the end of treatment at 4 hours

  2. Positive end-expiratory pressure

    Positive end-expiratory pressure will be measured during standard and modified high-flow tracheal oxygen.

    Time frame: From enrollment to the end of treatment at 4 hours

  3. Change of end-expiatory lung volume

    Change of end-expiatory lung volume will be measured during standard and modified high-flow tracheal oxygen.

    Time frame: From enrollment to the end of treatment at 4 hours

Secondary outcomes

  1. Respiratory rate

    Respiratory rate will be measured during standard and modified high-flow tracheal oxygen.

    Time frame: From enrollment to the end of treatment at 4 hours

  2. Tidal volume

    Tidal volume will be measured during standard and modified high-flow tracheal oxygen.

    Time frame: From enrollment to the end of treatment at 4 hours

  3. End-tidal carbon dioxide

    End-tidal carbon dioxide will be measured during standard and modified high-flow tracheal oxygen.

    Time frame: From enrollment to the end of treatment at 4 hours

  4. Pulse oxygen saturation

    Pulse oxygen saturation will be measured during standard and modified high-flow tracheal oxygen.

    Time frame: From enrollment to the end of treatment at 4 hours

  5. Esophageal pressure-time product

    Esophageal pressure-time product will be measured during standard and modified high-flow tracheal oxygen.

    Time frame: From enrollment to the end of treatment at 4 hours

  6. Tidal swing of esophageal pressure

    Tidal swing of esophageal pressure will be measured during standard and modified high-flow tracheal oxygen.

    Time frame: From enrollment to the end of treatment at 4 hours

  7. Respiratory muscle pressure

    Respiratory muscle pressure will be measured during standard and modified high-flow tracheal oxygen.

    Time frame: From enrollment to the end of treatment at 4 hours

  8. Dynamic transpulmonary pressure

    Dynamic transpulmonary pressure will be measured during standard and modified high-flow tracheal oxygen.

    Time frame: From enrollment to the end of treatment at 4 hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2025; primary completion for Nov 2025, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2025
First posted
Feb 10, 2025
StartEst.
Feb 20, 2025
Primary completionEst.
Nov 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Feb 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06816745
Lead sponsor
Jian-Xin Zhou
Responsible party
Jian-Xin Zhou (Professor, Capital Medical University) — Sponsor-investigator
First posted
Feb 10, 2025
Start date
Feb 20, 2025 (estimated)
Primary completion
Nov 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Feb 10, 2025

Study contacts

Jian-Xin Zhou, MD, PhD
Contact
zhoujx.cn@icloud.com
8610 6392 6666
Shan-Shan Xu, MD
Contact
1004496285@qq.com
8618501219133
Jian-Xin Zhou, MD, PhD
principal investigator · Capital Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion